Miraculins Announces Debt Extension from Secured Lenders

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic and risk assessment technologies for unmet clinical needs, announces
that it has entered into amending agreements to extend its CDN$1,000,000
nonconvertible secured loan with Gretchen Ross (the "2011 Lender") that was
originally announced on October 13, 2011 and previously extended on December 23,
2013, and to extend its CDN$611,334 nonconvertible secured loan from a third
party lender (the "2013 Lender") that was originally announced on December 23,
2013.


The loans have been extended and will now mature on December 31, 2015. The loans
will continue to bear interest at 12% per annum and the interest will accrue
until December 31, 2015.


As consideration for the extension of the loans, the Company will, subject to
regulatory approval, issue 500,000 common shares to the 2011 Lender and 500,000
common shares to the 2013 Lender. 


All of the shares to be issued to the 2011 Lender and the 2013 Lender will be
subject to resale restrictions for a period of four months from the date of
issuance under applicable securities legislation.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
過去株価チャート
から 5 2024 まで 6 2024